Aratana Therapeutics Inc.

Aratana Therapeutics Inc. is a pet therapeutics company, founded in 2010, and a wholly owned subsidiary of Elanco Animal Health. The company's slogan "Aratana Therapeutics is a wholly owned subsidiary of Elanco Animal Health" emphasizes its association with Elanco. Aratana Therapeutics is focused on the development and commercialization of innovative therapeutics for dogs and cats. The company's mission is to successfully develop and deliver best-in-class therapeutics, provide comprehensive service to veterinarians, and serve as a collaborator of choice for human and animal health companies. The company believes its therapeutics are highly differentiated, resolve recognizable needs in compelling markets, and have therapeutic profiles superior to the standard of care. Aratana Therapeutics' FDA-approved and commercially available therapeutics include a prostaglandin receptor antagonist that specifically targets the EP4 receptor to address osteoarthritis pain and inflammation in dogs, a selective ghrelin receptor agonist that stimulates appetite in dogs, and a long-acting, local anesthetic that provides up to 72 hours post-operative pain relief following certain surgeries in dogs and cats. The company operates in the biotechnology, healthcare, and pharmaceutical industries and is based in the United States. The last investment in Aratana Therapeutics was a $11.70M Post-IPO Equity investment on 15 March 2018, indicating continued investor interest in the company's growth and product development. The specific investors involved in this latest investment round are not disclosed.